![David Lovejoy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Lovejoy
Plus aucun poste en cours
Fortune : 49 104 $ au 31/05/2024
Historique de carrière de David Lovejoy
Anciens postes connus de David Lovejoy
Sociétés | Poste | Début | Fin |
---|---|---|---|
University of Toronto | Corporate Officer/Principal | - | - |
PROTAGENIC THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 03/02/1994 | - |
Fondateur | 03/02/1994 | - | |
Protagenic Therapeutics, Inc. /Old/
![]() Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Directeur Technique/Scientifique/R&D | - | - |
Formation de David Lovejoy
University of Victoria | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
Canada | 3 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
PROTAGENIC THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Protagenic Therapeutics, Inc. /Old/
![]() Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- David Lovejoy
- Expérience